| Ytd | -32.02% | |
| 1y | -72.09% |
| Open | 2.40 | Prev Close | 2.41 | Low | 2.38 | High | 2.44 | Mkt Cap | 224.33M |
| Vol | 920.59K | Avg Vol | 923.58K | EPS | -0.14 | P/E | N/A | Forward P/E | -17.25 |
| Beta | 0.60 | Short Ratio | 10.82 | Inst. Own | 32.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-24 | 50-d Avg | 2.85 | 200-d Avg | 3.45 | 1yr Est | 35.47 |
AVXL News
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an inve
-- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to
-- Proxy advisor recommends voting “ FOR” two of PVG's director nominees and “AGAINST” two incumben
Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic C
-- Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destru
ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS' Recommendation a
CENTENNIAL, Colo., Sept. 10, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockhol
Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS I
CENTENNIAL, Colo., Sept. 09, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockhol
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”)
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”)
CENTENNIAL, Colo., Sept. 01, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corporation (“PVG”), toge
Anavex Life Sciences (AVXL) has experienced a significant stock increase following its Q3 update, hi
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly earnings of $0.08 per share which beat the ana
Clinical Development Strategy for Alzheimer's Disease Remains the Focus as Anavex Advances Regulator
Launches VoteAnavex.com to Provide Additional Information on Anavex's Director Nominees and How to
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Dee
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.06) per share which beat the ana
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasd
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (N
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (N
Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD)
Findings underpin the scientific rationale for Anavex's targeted autophagy approach with orally admi
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”)
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp
US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur
Anavex shares fall after pulling EU filing for blarcamesine in Alzheimer's; EMA feedback prompts
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared
New study links early brain cleanup failure to Alzheimer's, supporting Anavex Life drug approach
Anavex highlighted a new peer-reviewed study published by University of California in Proceedings of
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
Anavex Life Sciences' stock rises despite no news, up over 40% this year as investors watch Alzh
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.06) per share which beat the ana
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), today announc
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-st
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an